Want to see SE:CARA full AI Analyst Report?
CARA Stock Chart & Stats
kr29.00
-kr0.28(-1.22%)
At close: 4:00 PM EST
kr29.00
-kr0.28(-1.22%)
Day’s Range― - ―
52-Week Rangekr21.70 - kr29.45
Previous CloseN/A
Volume42.56K
Average Volume (3M)72.78K
Market Cap
kr1.80B
Enterprise Valuekr1.74B
Total Cash (Recent Filing)kr47.10M
Total Debt (Recent Filing)kr25.41M
Price to Earnings (P/E)47.2
Beta0.21
Next Earnings
Feb 04, 2027EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend Yield15.83%
Share Statistics
EPS (TTM)0.57
Shares Outstanding70,324,780
10 Day Avg. Volume107,484
30 Day Avg. Volume72,778
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)2.36
Price to Sales (P/S)5.54
P/FCF Ratio-4.00K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.34
Revenue Forecast (FY)kr414.48M
Bulls Say, Bears Say
Bulls Say
Strong Growth And Customer ExpansionStrong growth, high net retention and low Nordic churn indicate that Carasent is expanding within existing accounts while winning new business. This supports recurring revenue durability, improves customer economics and provides a foundation for continued growth over the next several quarters.
Improved Profitability And Cash GenerationThe return to profitability alongside positive operating and free cash flow shows that the business is converting its recurring software activity into financial resources. Stronger cash generation can fund product investment, support resilience and improve the sustainability of future expansion.
Conservative Balance SheetVery low leverage gives Carasent meaningful financial flexibility and limits the burden of interest or refinancing requirements. This strengthens the company’s ability to invest in products such as MedSum, absorb execution issues and pursue growth without relying heavily on additional debt.
Bears Say
Germany Execution And Churn PressureGerman churn and the delayed Webcur rollout weaken near-term revenue conversion in an important market and create uncertainty around customer retention. Prolonged execution problems could offset Nordic momentum, increase replacement costs and delay the benefits expected from the new platform.
Modest Margins And Rising CostsOperating profitability remains modest for a software business, while planned German hiring and MedSum certification will raise expenses before their benefits are fully realized. This may limit margin expansion and make earnings more sensitive to implementation timing and revenue growth.
Slow Healthcare Adoption And MedSum HurdlesSlow healthcare technology adoption can lengthen sales cycles and defer the contribution of new products. MedSum’s demanding accuracy requirement and ongoing certification work may also delay functionality, limiting adoption speed and postponing the product’s potential growth impact.
Carasent AB News
CARA FAQ
What was Carasent AB’s price range in the past 12 months?
Carasent AB lowest stock price was kr21.70 and its highest was kr29.45 in the past 12 months.
What is Carasent AB’s market cap?
Carasent AB’s market cap is kr1.80B.
When is Carasent AB’s upcoming earnings report date?
Carasent AB’s upcoming earnings report date is Feb 04, 2027 which is in 101 days.
How were Carasent AB’s earnings last quarter?
Carasent AB released its earnings results on Oct 15, 2026. The company reported kr0.15 earnings per share for the quarter, beating the consensus estimate of kr0.12 by kr0.03.
Is Carasent AB overvalued?
According to Wall Street analysts Carasent AB’s price is currently Overvalued.
Does Carasent AB pay dividends?
Carasent AB pays a Notavailable dividend of kr1.84 which represents an annual dividend yield of 15.83%. See more information on Carasent AB dividends here
What is Carasent AB’s EPS estimate?
Carasent AB’s EPS estimate is 0.17.
How many shares outstanding does Carasent AB have?
Carasent AB has 70,324,780 shares outstanding.
What happened to Carasent AB’s price movement after its last earnings report?
Carasent AB reported an EPS of kr0.15 in its last earnings report, beating expectations of kr0.12. Following the earnings report the stock price went up 4.579%.
Which hedge fund is a major shareholder of Carasent AB?
Currently, no hedge funds are holding shares in SE:CARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Carasent AB
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden.
Technical Analysis
24SevenOffice
―
Lime Technologies AB
―
Vitec Software Group AB Class B
―
Upsales Technology AB
―
Oneflow AB
―